×
S&P 500   3,824.22 (-0.03%)
DOW   30,921.28 (-0.57%)
QQQ   285.59 (+1.23%)
AAPL   140.88 (+1.40%)
MSFT   261.73 (+0.83%)
META   166.88 (+4.28%)
GOOGL   2,255.00 (+3.69%)
AMZN   113.14 (+3.27%)
TSLA   694.33 (+1.84%)
NVDA   148.47 (+2.23%)
NIO   22.02 (+3.09%)
BABA   118.36 (+2.03%)
AMD   74.50 (+1.13%)
MU   56.49 (+5.29%)
CGC   2.67 (-4.98%)
T   21.14 (-0.80%)
GE   61.81 (-2.72%)
F   11.09 (-2.03%)
DIS   96.77 (+0.66%)
AMC   12.61 (-6.80%)
PFE   51.50 (-1.55%)
PYPL   74.21 (+3.94%)
NFLX   184.44 (+2.50%)
S&P 500   3,824.22 (-0.03%)
DOW   30,921.28 (-0.57%)
QQQ   285.59 (+1.23%)
AAPL   140.88 (+1.40%)
MSFT   261.73 (+0.83%)
META   166.88 (+4.28%)
GOOGL   2,255.00 (+3.69%)
AMZN   113.14 (+3.27%)
TSLA   694.33 (+1.84%)
NVDA   148.47 (+2.23%)
NIO   22.02 (+3.09%)
BABA   118.36 (+2.03%)
AMD   74.50 (+1.13%)
MU   56.49 (+5.29%)
CGC   2.67 (-4.98%)
T   21.14 (-0.80%)
GE   61.81 (-2.72%)
F   11.09 (-2.03%)
DIS   96.77 (+0.66%)
AMC   12.61 (-6.80%)
PFE   51.50 (-1.55%)
PYPL   74.21 (+3.94%)
NFLX   184.44 (+2.50%)
S&P 500   3,824.22 (-0.03%)
DOW   30,921.28 (-0.57%)
QQQ   285.59 (+1.23%)
AAPL   140.88 (+1.40%)
MSFT   261.73 (+0.83%)
META   166.88 (+4.28%)
GOOGL   2,255.00 (+3.69%)
AMZN   113.14 (+3.27%)
TSLA   694.33 (+1.84%)
NVDA   148.47 (+2.23%)
NIO   22.02 (+3.09%)
BABA   118.36 (+2.03%)
AMD   74.50 (+1.13%)
MU   56.49 (+5.29%)
CGC   2.67 (-4.98%)
T   21.14 (-0.80%)
GE   61.81 (-2.72%)
F   11.09 (-2.03%)
DIS   96.77 (+0.66%)
AMC   12.61 (-6.80%)
PFE   51.50 (-1.55%)
PYPL   74.21 (+3.94%)
NFLX   184.44 (+2.50%)
S&P 500   3,824.22 (-0.03%)
DOW   30,921.28 (-0.57%)
QQQ   285.59 (+1.23%)
AAPL   140.88 (+1.40%)
MSFT   261.73 (+0.83%)
META   166.88 (+4.28%)
GOOGL   2,255.00 (+3.69%)
AMZN   113.14 (+3.27%)
TSLA   694.33 (+1.84%)
NVDA   148.47 (+2.23%)
NIO   22.02 (+3.09%)
BABA   118.36 (+2.03%)
AMD   74.50 (+1.13%)
MU   56.49 (+5.29%)
CGC   2.67 (-4.98%)
T   21.14 (-0.80%)
GE   61.81 (-2.72%)
F   11.09 (-2.03%)
DIS   96.77 (+0.66%)
AMC   12.61 (-6.80%)
PFE   51.50 (-1.55%)
PYPL   74.21 (+3.94%)
NFLX   184.44 (+2.50%)
NASDAQ:RETA

Reata Pharmaceuticals Stock Forecast, Price & News

$34.80
+4.36 (+14.32%)
(As of 07/5/2022 03:21 PM ET)
Add
Compare
Today's Range
$30.72
$34.80
50-Day Range
$20.71
$34.76
52-Week Range
$20.24
$144.70
Volume
20,648 shs
Average Volume
393,053 shs
Market Capitalization
$1.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.00

Reata Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
76.3% Upside
$59.00 Price Target
Short Interest
Bearish
17.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.94mentions of Reata Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($8.34) to ($6.50) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.42 out of 5 stars

Medical Sector

128th out of 1,428 stocks

Pharmaceutical Preparations Industry

49th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Reata Pharmaceuticals logo

About Reata Pharmaceuticals (NASDAQ:RETA) Stock

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

RETA Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Copper More Critical than Lithium?
Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found.
Recap: Reata Pharmaceuticals Q4 Earnings
RETA SHAREHOLDER ALERT: Jakubowitz Law Reminds...
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RETA
Fax
N/A
Employees
346
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
7/05/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$59.00
High Stock Price Forecast
$112.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+69.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.66666666666667
Research Coverage
6 Analysts

Profitability

Net Income
$-297,390,000.00
Net Margins
-2,650.72%
Pretax Margin
-2,654.25%

Debt

Sales & Book Value

Annual Sales
$11.49 million
Book Value
$5.11 per share

Miscellaneous

Free Float
26,211,000
Market Cap
$1.27 billion
Optionable
Optionable
Beta
1.14














Reata Pharmaceuticals Frequently Asked Questions

Should I buy or sell Reata Pharmaceuticals stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Reata Pharmaceuticals stock.
View analyst ratings for Reata Pharmaceuticals
or view top-rated stocks.

What is Reata Pharmaceuticals' stock price forecast for 2022?

6 brokers have issued 12 month price objectives for Reata Pharmaceuticals' stock. Their RETA stock forecasts range from $35.00 to $112.00. On average, they expect Reata Pharmaceuticals' share price to reach $59.00 in the next twelve months. This suggests a possible upside of 71.8% from the stock's current price.
View analysts' price targets for Reata Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Reata Pharmaceuticals' stock performed in 2022?

Reata Pharmaceuticals' stock was trading at $26.37 on January 1st, 2022. Since then, RETA shares have increased by 30.2% and is now trading at $34.34.
View the best growth stocks for 2022 here
.

When is Reata Pharmaceuticals' next earnings date?

Reata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Reata Pharmaceuticals
.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) released its earnings results on Tuesday, May, 10th. The company reported ($2.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.23. The firm had revenue of $0.91 million for the quarter, compared to analyst estimates of $1.55 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 137.52% and a negative net margin of 2,650.72%. The firm's quarterly revenue was down 3.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.86) EPS.
View Reata Pharmaceuticals' earnings history
.

Who are Reata Pharmaceuticals' key executives?

Reata Pharmaceuticals' management team includes the following people:
  • Mr. J. Warren Huff, Chairman & CEO (Age 68, Pay $642.4k)
  • Mr. Manmeet Singh Soni, COO, CFO & Pres (Age 44, Pay $1.15M)
  • Mr. Michael D. Wortley, Exec. VP & Chief Legal Officer (Age 74, Pay $563.22k)
  • Dr. Colin J. Meyer M.D., Exec. VP & Chief Innovation Officer (Age 43, Pay $742.5k)
  • Ms. Dawn Carter Bir, Exec. VP & Chief Commercial Officer (Age 51, Pay $569.42k)
  • Mr. Bhaskar Anand, VP & Chief Accounting Officer (Age 45)
  • Dr. W. Christian Wigley Ph.D., Sr. VP & Chief Scientific Officer
  • Mr. Dakota Gallivan, VP & Chief Healthcare Compliance Officer
  • Mr. Steve Harman, Sr. VP & Chief HR Officer
  • Ms. Elaine Castellanos, Consultant (LinkedIn Profile)

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals CEO Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among Reata Pharmaceuticals' employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering (IPO) on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $34.34.

How much money does Reata Pharmaceuticals make?

Reata Pharmaceuticals (NASDAQ:RETA) has a market capitalization of $1.25 billion and generates $11.49 million in revenue each year. The company earns $-297,390,000.00 in net income (profit) each year or ($8.35) on an earnings per share basis.

How many employees does Reata Pharmaceuticals have?

Reata Pharmaceuticals employs 346 workers across the globe.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The official website for Reata Pharmaceuticals is www.reatapharma.com. The company can be reached via phone at (972) 865-2219 or via email at ir@reatapharma.com.

This page (NASDAQ:RETA) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.